SAN FRANCISCO -- In an era dominated by pricey, high-tech drugs, the humble aspirin had a practice-changing impact on colorectal cancer (CRC) recurrence, according to a randomized study reported here.

The researchers found that after 3 years of follow-up, time to recurrence was lower for participants assigned to aspirin versus placebo. A similar trend was seen for disease-free survival hazard ...

Low-dose aspirin significantly reduced colorectal cancer recurrence in patients with PI3K pathway gene alterations, nearly halving recurrence rates over three years compared to placebo. The study ...

A new clinical trial tested low-dose aspirin in patients with colon and rectal cancer, also referred to as colorectal cancer. The researchers wanted to see if taking aspirin daily could help prevent ...

Low-dose aspirin reduced colorectal cancer (CRC) recurrence rates by more than half in patients with tumors harboring mutations in the PI3K signaling pathway, according to findings from the phase 3 ...

A new international clinical trial led by the National Cancer Center Singapore is reporting that three years of aspirin following standard adjuvant therapy for high-risk Dukes' B and C colorectal ...

One large study found that more advanced cases of colorectal cancer had a higher likelihood of returning. For example, if participants had stage 3 colon cancer, almost 25 percent experienced a ...

Colon and rectal cancer disproportionately impact the Black community. A new study published in the Journal of Clinical Oncology suggests that a common over-the-counter drug may significantly reduce ...

Recurrence risk for stage II to III colon cancer falls below 0.5% 6 years posttreatment, suggesting a potential cure definition. The study analyzed data from 15 phase 3 trials, involving 35,213 ...

A retrospective study of patients with distal rectal cancer at Memorial Sloan Kettering Cancer Center (MSK) has found a higher rate of local recurrence after intersphincteric resection with handsewn ...

An experimental cancer vaccine has shown promise in keeping certain cancers from coming back. In a phase 1 clinical trial led in part by the UCLA Health Jonsson Comprehensive Cancer Center, ...